Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Victor H F Lee

Showing results (1-10 of 61) with videos related to

Pageof 7
Sort By:
Asia-Pacific Journal of Clinical Oncology|March 7, 2018
Case sharing of a patient re-challenged with afatinib for EGFR-mutated advanced non-small cell lung cancerVictor H F Lee
Annals of Translational Medicine|August 30, 2016
The aftermath of LUX-Lung 7 study-what have we learnt from it?Victor H F Lee
International Journal of Radiation Oncology, Biology, Physics|September 5, 2020
Will the COVID Pandemic Lead to Uncounted Cancer Deaths in the Future?Jason W Chan, Victor H F Lee
Hepatology (Baltimore, Md.)|February 2, 2022
ReplyVictor H F Lee, Tiffany C L Wong
BMC Bioinformatics|March 9, 2018
Prediction of sensitivity to gefitinib/erlotinib for EGFR mutations in NSCLC based on structural interaction fingerprints and multilinear principal component analysisBin Zou, Victor H F Lee, Hong Yan
Hong Kong Medical Journal = Xianggang Yi Xue Za Zhi|November 28, 2013
Effectiveness and cost-effectiveness of erlotinib versus gefitinib in first-line treatment of epidermal growth factor receptor-activating mutation-positive non-small-cell lung cancer patients in Hong KongVivian W Y Lee, Bjoern Schwander, Victor H F Lee
Oral Oncology|January 28, 2014
Novel therapy for nasopharyngeal carcinoma--where are weJanice Tsang, Victor H F Lee, Dora L W Kwong
Lancet (London, England)|February 26, 2023
Hyperfractionation for reirradiation of recurrent nasopharyngeal carcinomaMelvin L K Chua, Victor H F Lee, Anne W M Lee
Plos One|May 21, 2015
Contribution of EGFR and ErbB-3 Heterodimerization to the EGFR Mutation-Induced Gefitinib- and Erlotinib-Resistance in Non-Small-Cell Lung Carcinoma TreatmentsDebby D Wang, Lichun Ma, Maria P Wong, et al.
IEEE/ACM Transactions on Computational Biology and Bioinformatics|January 10, 2022
Computational Methods for the Analysis and Prediction of EGFR-Mutated Lung Cancer Drug Resistance: Recent Advances in Drug Design, Challenges and Future ProspectsRizwan Qureshi, Bin Zou, Tanvir Alam, et al.
Pageof 7

Showing results (1-10 of 61) with videos related to

Sort By:
Pageof 7
Asia-Pacific Journal of Clinical Oncology|March 7, 2018
Case sharing of a patient re-challenged with afatinib for EGFR-mutated advanced non-small cell lung cancerVictor H F Lee
Annals of Translational Medicine|August 30, 2016
The aftermath of LUX-Lung 7 study-what have we learnt from it?Victor H F Lee
International Journal of Radiation Oncology, Biology, Physics|September 5, 2020
Will the COVID Pandemic Lead to Uncounted Cancer Deaths in the Future?Jason W Chan, Victor H F Lee
Hepatology (Baltimore, Md.)|February 2, 2022
ReplyVictor H F Lee, Tiffany C L Wong
BMC Bioinformatics|March 9, 2018
Prediction of sensitivity to gefitinib/erlotinib for EGFR mutations in NSCLC based on structural interaction fingerprints and multilinear principal component analysisBin Zou, Victor H F Lee, Hong Yan
Hong Kong Medical Journal = Xianggang Yi Xue Za Zhi|November 28, 2013
Effectiveness and cost-effectiveness of erlotinib versus gefitinib in first-line treatment of epidermal growth factor receptor-activating mutation-positive non-small-cell lung cancer patients in Hong KongVivian W Y Lee, Bjoern Schwander, Victor H F Lee
Oral Oncology|January 28, 2014
Novel therapy for nasopharyngeal carcinoma--where are weJanice Tsang, Victor H F Lee, Dora L W Kwong
Lancet (London, England)|February 26, 2023
Hyperfractionation for reirradiation of recurrent nasopharyngeal carcinomaMelvin L K Chua, Victor H F Lee, Anne W M Lee
Plos One|May 21, 2015
Contribution of EGFR and ErbB-3 Heterodimerization to the EGFR Mutation-Induced Gefitinib- and Erlotinib-Resistance in Non-Small-Cell Lung Carcinoma TreatmentsDebby D Wang, Lichun Ma, Maria P Wong, et al.
IEEE/ACM Transactions on Computational Biology and Bioinformatics|January 10, 2022
Computational Methods for the Analysis and Prediction of EGFR-Mutated Lung Cancer Drug Resistance: Recent Advances in Drug Design, Challenges and Future ProspectsRizwan Qureshi, Bin Zou, Tanvir Alam, et al.
Pageof 7